Sanara Medtech Inc. — Filing Summary
Issuer identification: The supplied filing is for Wound Management Technologies, Inc. (WMT), not Sanara Medtech Inc.; the text does not explain a relationship between the companies. Verify the issuer and filing before relying on this summary.
Business context and reporting period
This is WMT’s Form 10-K for the fiscal year ended December 31, 2014, filed April 9, 2015. It reports annual results, not standalone fourth-quarter results. WMT markets CellerateRX collagen-based wound-care products and earns licensing royalties through its orthopedic-products subsidiary. Its principal product patent expires in 2018.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $2.63 million | $1.73 million |
| Gross profit / margin | $1.83 million / 69.5% | $0.93 million / 54.1% |
| Operating loss | $2.06 million | $2.93 million |
| Net loss | $2.28 million | $4.15 million |
| Net loss available to common shareholders | $2.51 million | $4.15 million |
| Net cash used in operations | $1.69 million | $1.82 million |
- Revenue grew 52%, driven by product sales and $252,000 in ROP/BioStructures fees and royalties. Gross margin improved as revenue rose while cost of goods sold increased only 1%.
- General and administrative expense was nearly flat at $3.84 million. Interest expense fell 83% to $294,000, largely because debt was repaid or converted to equity. The company remained loss-making.
- Year-end cash was $523,441, up from $44,553. Current assets were $1.21 million against current liabilities of $2.32 million, a working-capital deficit of approximately $1.10 million and a current ratio of about 0.52.
- Notes and convertible notes payable totaled $1.59 million at year-end, excluding $181,431 of accrued interest. Total liabilities were $2.32 million. The $1.0 million BMI note and $200,000 drawdown balance were due April 15, 2015 after an extension; the notes are secured by company and subsidiary assets and carry 8% interest.
- Financing activities provided $2.17 million, mainly from $2.25 million of Series C preferred stock sales. The company reported 5% annual Series C dividends through October 2016, then 3% through October 2018; the shares are convertible into common stock.
Material changes versus 2013
- Revenue increased 52%; net loss narrowed 45%. Operating loss also declined, while reported gross margin improved substantially.
- Cash increased by about $479,000, supported by equity financing. Operating activities continued to consume cash.
- Derivative liabilities fell from $1.04 million to $1,708, primarily following debt conversions/payoffs and changes in warrant classification. This reduced a significant balance-sheet liability but is not equivalent to operating cash generation.
- WMT raised common-share authorization from 100 million to 250 million; outstanding Series D preferred shares converted into common shares. Common shares issued at year-end were 92.9 million, compared with 85.7 million a year earlier.
Outlook, risks, contingencies, and unusual items
- Management expected momentum to continue in 2015, with greater hospital penetration, international distribution, and possible launch of a product in at least one adjacent market with a strategic partner. WMT also anticipated introducing its resorbable bone-wax product in 2015, subject to FDA clearance and further testing. These are forward-looking plans, not guaranteed outcomes.
- The auditor issued an unmodified opinion but highlighted substantial doubt about WMT’s ability to continue as a going concern, citing recurring losses, a working-capital deficit, and accumulated deficit. Management said additional financing was needed in 2015; funding was not assured.
- WMT relies on a single manufacturer and inventory vendor for CellerateRX. Two customers accounted for approximately 27% and 10% of 2014 sales. The CellerateRX patent expires in 2018; competition, reimbursement changes, and the ability to fund sales growth are material risks.
- A lawsuit concerning a disputed promissory note remained unresolved, with trial reset for July 2015. A second note-related lawsuit was filed in February 2015 and was set for trial in October 2015. The company said it could not determine the outcomes or financial effects.
- WMT had settled an SEC action with a permanent injunction and a $20,000 civil penalty; final judgment was entered in January 2013. Separately, $324,286 of year-end royalties payable was paid in January 2015.
- Disclosure controls and internal control over financial reporting were assessed by management as effective at year-end; the auditor was not engaged to provide an opinion on internal-control effectiveness.
Important facts for investors to verify
- Confirm that Wound Management Technologies, Inc. is the intended issuer; the filing text does not identify Sanara Medtech Inc.
- Check the status and repayment, refinancing, or conversion of BMI debt due April 15, 2015, and the company’s subsequent financing and cash runway.
- Review subsequent operating results to assess whether revenue growth, gross margin improvement, and hospital sales expansion continued.
- Verify the outcomes and any financial consequences of the Link and Beeleve lawsuits, and confirm payment of accrued royalties.
- Assess dilution and voting effects from Series C preferred stock, common-stock issuances, options, and warrants; the filing reports 10.94 million warrants outstanding at year-end.